Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Plus Regorafenib in HCC After Camrelizumab and Apatinib Failure
NCT06280105Phase 2Recruiting
- Sponsor
- Mengchao Hepatobiliary Hospital of Fujian Medical University
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Mengchao Hepatobiliary Hospital of Fujian Medical University. Started Mar 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06280105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06280105.